|
|
Vaccine Detail
|
IL15-DC Vaccine |
| Vaccine Information |
- Vaccine Name: IL15-DC Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: whole cell cancer vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: IL15, melanoma/HIV peptides, and KLH (NCT01189383)
- Immunization Route: subcutaneous injection
- Description: Autologous dendritic cells are manufactured with GM-CSF, IL15 and loaded with melanoma/HIV peptides and KLH; then activated with LPS and CD40 Ligand.IL15 is a T cell growth factor that could have a very important role in cancer immunotherapy. IL15 DCs are particularly efficient at priming functional melanoma specific CD8+ T cells. The use of IL15 in the manufacture of the DC vaccine could result in an improved immunotherapy product for melanoma patients. (NCT01189383)
|
| Host Response |
|
|
| References |
NCT01189383: IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma [https://clinicaltrials.gov/study/NCT01189383]
|
|
